Robyn Karnauskas
Stock Analyst at Truist Securities
(1.88)
# 3,138
Out of 4,918 analysts
183
Total ratings
42.04%
Success rate
-0.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.24 | +135.85% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $296.88 | +0.38% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $44.23 | +46.96% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $79.29 | +38.73% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $113.18 | -26.67% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $195.22 | +7.57% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.57 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $131.95 | +157.67% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.63 | +1,495.09% | 2 | May 15, 2024 | |
| CHRS Coherus Oncology | Maintains: Buy | $8 → $7 | $0.88 | +697.45% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $558.87 | +103.09% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.92 | +420.83% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.90 | +210.34% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $21.95 | +237.13% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.31 | +103.36% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $15.71 | +205.54% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $9.16 | +445.85% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $762.33 | +11.50% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $462.13 | +9.93% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $23.49 | +53.26% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $52.13 | -52.04% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.37 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $58.14 | +140.80% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.04 | +383,531.71% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.07 | +554.21% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $13.70 | +301.61% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.87 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $22.50 | +1,322.22% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $6.65 | +125.56% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.44 | +19,187.50% | 1 | Oct 8, 2020 |
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.24
Upside: +135.85%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $296.88
Upside: +0.38%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $44.23
Upside: +46.96%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $79.29
Upside: +38.73%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $113.18
Upside: -26.67%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $195.22
Upside: +7.57%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.57
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $131.95
Upside: +157.67%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.63
Upside: +1,495.09%
Coherus Oncology
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.88
Upside: +697.45%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $558.87
Upside: +103.09%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.92
Upside: +420.83%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.90
Upside: +210.34%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $21.95
Upside: +237.13%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.31
Upside: +103.36%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $15.71
Upside: +205.54%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $9.16
Upside: +445.85%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $762.33
Upside: +11.50%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $462.13
Upside: +9.93%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $23.49
Upside: +53.26%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $52.13
Upside: -52.04%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.37
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $58.14
Upside: +140.80%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $0.04
Upside: +383,531.71%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.07
Upside: +554.21%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $13.70
Upside: +301.61%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $4.87
Upside: -
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $22.50
Upside: +1,322.22%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $6.65
Upside: +125.56%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.44
Upside: +19,187.50%